Christopher Logothetis
Overview
Explore the profile of Christopher Logothetis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
4158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Soundararajan R, Viscuse P, Pilie P, Liu J, Logotheti S, Laberiano Fernandez C, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35805010
The aggressive variant prostate cancer molecular profile (AVPC-m), composed of combined defects in TP53, RB1 and PTEN, characterizes a subset of prostate cancers linked to androgen indifference and platinum sensitivity....
12.
Bondaruk J, Jaksik R, Wang Z, Cogdell D, Lee S, Chen Y, et al.
iScience
. 2022 Jun;
25(7):104551.
PMID: 35747385
Whole-organ mapping was used to study molecular changes in the evolution of bladder cancer from field effects. We identified more than 100 dysregulated pathways, involving immunity, differentiation, and transformation, as...
13.
Vellano C, White M, Andrews M, Chelvanambi M, Witt R, Daniele J, et al.
Nature
. 2022 Jun;
606(7915):797-803.
PMID: 35705814
Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized care in melanoma and other cancers; however, therapeutic resistance is common and innovative treatment strategies are needed. Here we studied...
14.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):e18-e19.
PMID: 35440417
No abstract available.
15.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):6-11.
PMID: 35393158
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive...
16.
Shapiro D, Soeung M, Perelli L, Dondossola E, Surasi D, Tripathi D, et al.
Cancers (Basel)
. 2021 Dec;
13(23).
PMID: 34885132
Renal medullary carcinoma (RMC) is a lethal malignancy affecting individuals with sickle hemoglobinopathies. Currently, no modifiable risk factors are known. We aimed to determine whether high-intensity exercise is a risk...
17.
Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd P, et al.
Oncogene
. 2021 Sep;
40(44):6284-6298.
PMID: 34584218
Prostate cancer (PCa) that progresses after androgen deprivation therapy (ADT) remains incurable. The underlying mechanisms that account for the ultimate emergence of resistance to ADT, progressing to castrate-resistant prostate cancer...
18.
Grypari I, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, et al.
Medicine (Baltimore)
. 2021 Sep;
100(36):e27094.
PMID: 34516499
Epigenetic changes are implicated in prostate cancer (PCa) progression and resistance to therapy. Arginine residue methylation is an understudied histone post-translational modification that is increasingly associated with cancer progression and...
19.
Msaouel P, Oromendia C, Siefker-Radtke A, Tannir N, Subudhi S, Gao J, et al.
JAMA Netw Open
. 2021 Aug;
4(8):e2122998.
PMID: 34459906
Importance: Immune checkpoint inhibitors can produce distinct toxic effects that require prompt recognition and timely management. Objective: To develop a technology-enabled, dynamically adaptive protocol that can provide the accurate information...
20.
Pan T, Lin S, Lee Y, Yu G, Song J, Pan J, et al.
Oncogene
. 2021 Jun;
40(27):4592-4603.
PMID: 34127814
A fraction of patients undergoing androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) will develop recurrent castrate-resistant PCa (CRPC) in bone. Strategies to prevent CRPC relapse in bone are...